Kedrion Biopharma to be Honored for IVIG Therapy Innovation
Kedrion Biopharma will be recognized by Premier, Inc. for its QIVIGY® solution, which advances care for patients needing IVIG therapy. The award will be presented at Premier's annual Supplier Innovation Celebration.
Kedrion Biopharma will receive recognition from Premier, Inc. for its QIVIGY® solution, aimed at improving care for patients requiring IVIG therapy. The honor will be bestowed during Premier's annual Supplier Innovation Celebration, held in conjunction with the 2026 Breakthroughs Conference and Exhibition.
The QIVIGY® solution is designed to enhance how hospitals manage and deliver intravenous immunoglobulin therapy, a critical treatment for various autoimmune disorders and immunodeficiency conditions. This recognition highlights Kedrion's contributions to advancing healthcare technology and patient treatment.
Premier, Inc. is a prominent healthcare improvement company that provides integrated data and analytics, along with supply chain and other services, to hospitals and health systems. The company annually recognizes suppliers that demonstrate significant innovation and deliver value within the healthcare sector.
Kedrion Biopharma specializes in the production and distribution of plasma-derived therapeutic products. The company focuses on developing solutions to meet the needs of patients and healthcare systems.